Lazard Global Biopharmaceutical Leaders Study 2024

The Lazard Global Biopharmaceutical Leaders Study 2024 is an executive summary that presents findings from a survey conducted among 291 leaders in the biopharmaceutical sector. The study reflects on the previous year's expectations regarding market recovery, transaction activity, and therapeutic focus, noting a correlation between past predictions and actual industry developments. It highlights that 79% of respondents from the 2023 study did not anticipate a market recovery before the first half of 2024, while 90% expected large-cap consolidation to remain low. The report details the therapeutic priorities identified in the previous study, including autoimmune diseases and solid tumors, and discusses the impact of the Inflation Reduction Act on the industry. The findings indicate an increase in bolt-on acquisitions and collaborations, driven by the need for growth and innovation. Overall, the study captures the current state of the biopharmaceutical market, emphasizing ongoing innovation and the challenges posed by economic and regulatory factors.